Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has announced that its wholly owned subsidiary, Adelia Therapeutics Inc., has a achieved a significant milestone. Specific milestones outlined in the Dec. 4, 2021, contribution agreement define what actions are to be taken when certain milestones are reached. When this specific milestone, identified as Year 2 Q1 (v), is reached, the agreement calls for 15,611.4 class B common shares to be issued to Adelia shareholders; those shares are exchangeable for common shares in Cybin capital in accordance with parameters defined by the agreement. Adelia is committed to developing medicinal psychedelics that offer improved dosing efficacy and therapeutic indices designed to address unmet medical needs. Specifically, Adelia is focused on the development of treatment regimens consisting of proprietary psychedelic molecules and related clinical protocols.
To view the full press release, visit https://ibn.fm/7uvor
About Cybin Inc.
Cybin is a leading biotechnology company focused on researching and progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and potential treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire is part of the InvestorBrandNetwork.